Ftse Mib
34.799,27
-0,83%
DAX
20.132,85
-0,44%
S&P 500
5.836,22
0,16%
NASDAQ
19.088,10
-0,38%
Bitcoin
94.953,90
0,47%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Immutep Ltd (IMMP) Immutep Ltd (IMMP) Notizie

Immutep Ltd

IMMP
1,94
-0,07 (-3,48%)
14 Gen 2025 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Ricevuta di Deposito
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
06/1/202514:00GLOBEPatient Enrolment Completed for INSIGHT-003
17/12/202414:00GLOBEImmutep Announces Initial Safety Data from First-in-Human..
16/12/202414:00GLOBEImmutep and Monash University Announce First Publication..
12/12/202421:33EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12/12/202414:15GLOBEImmutep Reports Promising New Data in Head and Neck Cancer..
10/12/202423:26EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
10/12/202414:00GLOBEImmutep Announces Initiation of TACTI-004 Phase III Trial in..
14/11/202414:15GLOBEImmutep’s Efti Shows Excellent Survival Data from..
14/11/202414:00GLOBEPositive Data from Phase II Trial in Soft Tissue Sarcoma..
29/10/202413:00GLOBEImmutep Quarterly Activities Report Q1 FY25
28/10/202413:00GLOBEImmutep to Present New Phase IIb Data in PD-L1 Negative (CPS..
17/10/202414:00GLOBEImmutep Announces First-in-Human Phase I Study of IMP761..
10/10/202414:00GLOBEImmutep to Participate in the 2024 Maxim Healthcare Virtual..
03/10/202414:00GLOBEImmutep Completes Patient Enrolment in Randomised Phase II..
24/9/202414:00GLOBEImmutep Receives A$3.6 million R&D Tax Incentive from French..
24/9/202412:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
18/9/202414:00GLOBENew Data to be Presented from EFTISARC-NEO Phase II..
16/9/202414:00GLOBEImmutep’s Efti in Combination with MSD’s KEYTRUDA® Leads to..
10/9/202403:54EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/8/202414:00GLOBEImmutep Announces Late-Breaking Abstract in Head & Neck..
14/8/202414:00GLOBEImmutep Announces First Participant Dosed in Phase I Study..
07/8/202414:00GLOBEImmutep to Participate in Upcoming Investor Conferences
31/7/202414:00GLOBEImmutep Quarterly Activities Report Q4 FY24
22/7/202414:00GLOBEImmutep Announces Successful Meeting with FDA on Phase III..
17/7/202414:00GLOBEImmutep Receives Regulatory Clearance for Phase I Study of..
12/7/202400:40GLOBEImmutep Reports Positive Results in First Line Head and Neck..
03/7/202414:00GLOBEImmutep Announces Details for Oral Presentation at ESMO..
25/6/202414:00GLOBEImmutep Signs Exclusive License Agreement with Cardiff..
05/6/202412:00GLOBEImmutep successfully completes institutional placement and..
04/6/202413:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
03/6/202402:38GLOBEImmutep Announces Clinical Collaboration with MSD to..
15/5/202414:00GLOBEImmutep Presents Data from Safety Lead-in Phase of AIPAC-003..
02/5/202414:00GLOBEPositive Initial Clinical Data Reported from Immutep’s Efti..
29/4/202414:00GLOBEImmutep Quarterly Activities Report Q3 FY24
24/4/202414:00GLOBEImmutep Announces Positive Preliminary Topline Results from..
18/4/202414:00GLOBEImmutep Appoints Leading Research Institute to Conduct..
17/4/202414:00GLOBEImmutep Receives Positive Feedback from the Spanish..
05/3/202414:00GLOBEImmutep Announces First Clinical Data from 90mg Dosing of..
30/1/202422:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
30/1/202414:00GLOBEImmutep Quarterly Activities Report Q2 FY24
Apertura: 2,01 Min: 1,93 Max: 2,01
Chiusura: 2,01

La tua Cronologia

NASDAQ
IMMP
Immutep
BIT
NSCIT2203981
Asian Infrastructure Inv...
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network